โรงพยาบาลจุฬาลงกรณ์ เป็นโรงพยาบาลสังกัดสภากาชาดไทย ในเขตปทุมวัน กรุงเทพมหานคร ก่อตั้งขึ้นในปี พ.ศ. 2457

During the past decade, King Chulalongkorn Memorial Hospital conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 2 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 2 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "King Chulalongkorn Memorial Hospital" #1 sponsor was "Agios Pharmaceuticals, Inc." with 2 trials, followed by "Chulalongkorn University" with 1 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 1 trials sponsored, "Ionis Pharmaceuticals, Inc." with 1 trials sponsored and "Janssen Research & Development, LLC" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "King Chulalongkorn Memorial Hospital" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "King Chulalongkorn Memorial Hospital" are "Beta Thalassemia Intermedia" (1 trials), "Breast Neoplasms" (1 trials), "End-stage Renal Disease" (1 trials), "Lower Respiratory Tract Disease" (1 trials) and "Non-Transfusion-dependent Alpha-Thalassemia" (1 trials). Many other conditions were trialed in "King Chulalongkorn Memorial Hospital" in a lesser frequency.

Most popular intervention types in "King Chulalongkorn Memorial Hospital" are "Drug" (6 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Mitapivat" (2 trials), "Placebo Matching Mitapivat" (2 trials), "Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF" (1 trials) and "Hemodiafiltration" (1 trials). Other intervention names were less common.

The vast majority of trials in "King Chulalongkorn Memorial Hospital" are 7 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "King Chulalongkorn Memorial Hospital". undefined are not yet recruiting, 3 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in King Chulalongkorn Memorial Hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in King Chulalongkorn Memorial Hospital, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".